X

Trial Profile

Combination Talazoparib - Carboplatin for Recurrent High-grade Glioma With DNA Damage Repair Deficiency (DDRd)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Talazoparib (Primary)
Indications DNA repair deficiency disorders; Glioblastoma; Glioma; Gliosarcoma
Focus Therapeutic Use
Acronyms TAC-GReD

Most Recent Events

04 Jun 2024 Results(n=33) discussing about feasibility and efficacy of combination of talazoparib and carboplatin in DNA damage repair deficient recurrent high-grade glioma , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
10 Feb 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com